14 jan: SUPER SUPPER I EN KOLD TID
18 jan: Udsigt til stærkt 1. halvår på aktiemarkederne
14-01-2011 17:02:34

Ad hoc reports in accordance with Sec. 15 of the German Securities Trading Act - Dräger increases net sales in 2010 by around 14 percent

Drägerwerk AG & Co. KGaA /

Ad hoc reports in accordance with Sec. 15 of the German Securities Trading Act -

Dräger increases net sales in 2010 by around 14 percent

Processed and transmitted by Thomson Reuters.

The issuer is solely responsible for the content of this announcement.

EBIT margin at the upper limit of the forecast 

According to preliminary estimates, Drägerwerk AG & Co. KGaA achieved net sales growth of around 14 percent and record net sales of EUR 2.2 billion in 2010 compared to EUR 1.9 billion in 2009. In October 2010, the company still anticipated net sales growth around 10 percent. The EBIT margin reached 8 to 9 percent, the upper limit of the 2010 forecast. Order intake rose by around 9 percent year on year to EUR 2.2 billion. 

The medical division recorded order intake of around 8 percent and generated net sales of EUR 1.5 billion - an increase of approximately 17 percent compared to the previous year. The EBIT margin was around 12 percent according to preliminary estimates. In the safety division, order intake went up by about 10 percent and net sales reached EUR 0.7 billion, corresponding to a rise of around 9 percent compared to 2009. The EBIT margin came to around 9 percent according to preliminary estimates. 

The reasons for the positive net sales and earnings development were the unexpectedly high order intake in the fourth quarter of 2010, continuous positive developments in the Americas and Asia/Pacific and favorable currency effects. The turnaround program also had an extremely positive effect. 

In 2011, Dräger will invest even larger sums into research and development, implement projects even more quickly and improve its marketing and sales organization in particular. For this reason, Dräger expects slightly higher group net sales in 2011 and an EBIT margin between 7.5 percent and 8.5 percent. The estimated development of net sales and margins in fiscal year 2011 is based on the assumption that the markets relevant to Dräger will continue their steady development and that exchange rates will remain at the current level. In the medium term, the company plans to grow faster than the market and achieve a minimum EBIT margin of 10 percent in the long term.

 

Drägerwerk AG & Co. KGaA

Moislinger Allee 53-55

23558 Lübeck, Deutschland

www.draeger.com  

Investor Relations:

Vanina Hoffmann

Phone:+49 451 882-2685

vanina.hoffmann@draeger.com 

Corporate Communications:

Burkard Dillig

Phone +49 451 882-2185

burkard.dillig@draeger.com 

 

Disclaimer

This press release contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date and have been prepared to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors. They entail risks and uncertainties beyond the Company's control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, we assume no obligation to update the forward-looking statements contained in this report. You will find all other financial dates on our website at www.draeger.com under Investor Center/Financial Calendar.

Press release (PDF)

--- End of Message ---

Drägerwerk AG & Co. KGaA

Moislinger Allee 53-55 Lübeck Germany

Listed: Freiverkehr in Börse Stuttgart,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse,

Regulierter Markt in Bayerische Börse München,

Regulierter Markt in Börse Berlin,

Regulierter Markt in Hanseatische Wertpapierbörse zu Hamburg,

Regulierter Markt in Börse Düsseldorf,

Regulierter Markt in Niedersächsische Börse zu Hannover;

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Drägerwerk AG & Co. KGaA via Thomson Reuters ONE

HUG#1479951

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
19 mar
BAVA
Efter en fantastik uge vil jeg godt lige prøve at lave en evaluering af hvorfor jeg mener at der er ..
64
21 mar
PNDORA
  Jeg har flere gange analyseret Pandora, senest efter årsregnskabet. Den seneste tid har kursen vær..
59
21 mar
E:QEC
At jeg gør som jeg gør, og et lille indblik i hvilke gabs vi har liggende som sagtens kan fyldes på ..
24
23 mar
I:DAX
@marc55.   Lad mig give dig et velment råd.   Jeg er ikke en gammel sur mand (hverken gammel eller s..
18
21 mar
FING-B
Baronen84, jeg tager hatten af for dine RTX aktier, det er flot set :-)   Men at være hånlig overfor..
18
19 mar
I:DAX
Vorherre bevares!
18
22 mar
OMXC25
Det var så vigtigt vi skulle stemme. Jeg er glad for det blev et NEJ.   EU sagde vi ikke ville få en..
17
24 mar
RTX
vi er  mange der er glade for at slippe for dig. TAK TIL EI.
16
21 mar
VWS
idiot
15
23 mar
VWS
Dong Energy og Vestas får meldinger om off shore industrien, hvor de store olieselskaber øjnene muli..
14

Novo: EMA-udvalg anbefaler markedsføringstilladelse til Refixia - NY

24-03-2017 13:31:36
Udvalget for humanmedicinske lægemidler (CHMP) ved Det Europæiske Lægemiddelsagentur (EMA) har tildelt Novo Nordisks Refixia en positiv udtalelse og anbefaler en markedsføringstilladelse.Det skriver Novo Nordisk i en fondsbørsmeddelelse.CHMP anbefaler en markedsføringstilladelse til Refixia til unge og voksne med hæmofili B. Til grund for anbefalingen ligger resultater fra udviklingsprogrammet par..

Novo/Exane: Kursmålet skæres til 270 kr.

24-03-2017 10:17:22
Den franske storbank Exane BNP Paribas skærer kursmålet for aktien i Novo Nordisk til 270 kr. fra 295 kr. Anbefalingen er uændret "outperform", viser data fra Bloomberg.Novo-aktien falder fredag 0,4 pct., eller 1 kr., til 233,20 kr. Det dækker dog over en stigning, da aktien ikke længere handles inklusive retten til et udbytte på 4,60 kr./ritzau/FINANSJakob Dalskov +45 33 30 03 35 Ritzau Finans, E..

Aktier/tendens: Mulighed for mere gas til Mærsk i ventet rødt C20

24-03-2017 08:31:54
Det danske aktiemarked kan fredag blive præget af små udsving med en lille overvægt af negative fortegn.A.P. Møller-Mærsks B-aktie var uændret efter torsdagens handel og blev handlet til 11.500 kr. Aktien kan dog gå fra grå til grøn fredag, da der er potentielt gode nyheder til det danske konglomerat.Efter en Nordsø-aftale, der kan redde det ellers lukningstruede Tyra-felt, skriver Jyllands-Posten..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo/Exane: Kursmålet skæres til 270 kr.
2
Novo: EMA-udvalg anbefaler markedsføringstilladelse til Refixia - NY
3
Aktier/tendens: Mulighed for mere gas til Mærsk i ventet rødt C20
4
Novo er et skridt nærmere vigtigt markedsføringsargument for Tresiba
5
Aktier/åbning: Mærsks aktie stiger forsigtigt efter Svane-nyheder

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. marts 2017 07:01:34
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170324.2 - EUROWEB2 - 2017-03-25 07:01:34 - 2017-03-25 07:01:34 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x